BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 2020;112:764-72. [PMID: 32856231 DOI: 10.1007/s12185-020-02974-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Pavenski K, Huang SS, Patriquin CJ. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;:1-14. [PMID: 34747320 DOI: 10.1080/17474086.2021.2003703] [Reference Citation Analysis]
2 Uchino K, Sakai K, Shinohara S, Matsuhisa A, Iida Y, Nakano Y, Matsumura S, Kanasugi J, Takasugi S, Nakamura A, Horio T, Murakami S, Mizuno S, Yamamoto H, Hanamura I, Matsumoto M, Takami A. Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature. Int J Hematol 2022. [PMID: 35274194 DOI: 10.1007/s12185-022-03319-7] [Reference Citation Analysis]